Question 1

Am I eligible for this trial based on my current treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of INBRX-106 and pembrolizumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this combination treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks I should be aware of before joining this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) clinical trial (NCT04198766). Contact the study team or your healthcare provider for specific answers.

What this study is about